Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Best Defensive Stocks To Balance Tech Sector Volatility
08:30am, Thursday, 18'th Dec 2025
December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted
Incyte to Present at Upcoming Investor Conference
08:00am, Thursday, 18'th Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The pre
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
11:20am, Wednesday, 17'th Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma.
Incyte Announces Change to its Board of Directors
08:30am, Friday, 12'th Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Change to its Board of Directors.
Here's Why Incyte (INCY) is a Strong Value Stock
10:40am, Thursday, 11'th Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
12:59pm, Tuesday, 09'th Dec 2025
The Investment Committee debate the latest Calls of the Day.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET.
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
11:31am, Monday, 08'th Dec 2025
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer
09:27am, Monday, 08'th Dec 2025
Early ASH 2025 data shows Incyte's INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis.
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY
04:50am, Monday, 08'th Dec 2025
First Trust Advisors LP reduced its position in shares of Incyte Corporation (NASDAQ: INCY) by 1.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commissi
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
06:23pm, Sunday, 07'th Dec 2025
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug
12:58pm, Sunday, 07'th Dec 2025
The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
09:30am, Sunday, 07'th Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2
Incyte: Buy At This Inflection Point
09:00am, Saturday, 06'th Dec 2025
Incyte Corporation's rapid non-Jakafi portfolio growth and strong operating leverage look decent amid still-cheap valuation, supporting attractive risk-reward over the coming quarters ahead. Q3 revenu
